Jan Kral, MD, PhD, MSc, MBA's Avatar

Jan Kral, MD, PhD, MSc, MBA

@kraljan.bsky.social

Doctor at Charles University and Motol University Hospital, Prague. Ph.D. in colorectal cance. Researcher in obesity, AI, and 3D printing. ESGE Social Media Group. Passionate about GI health and innovation.

166 Followers  |  82 Following  |  12 Posts  |  Joined: 25.11.2024  |  1.5865

Latest posts by kraljan.bsky.social on Bluesky

Post image

🌟Vedolizumab & Ustekinumab: Safe for IBD Moms? 🌟

📊 Study: EPI-MERES registry (2014–2021).
🧪 Results:
✅ No extra risks vs. anti-TNFs.
⚠️ Ustekinumab: Slightly higher risk of small-for-gestational-age births.

💡 Conclusion: Reassuring safety, but more research needed!

05.01.2025 07:08 — 👍 0    🔁 0    💬 0    📌 0
Post image

🔬🚀 #CrohnsDisease News‼️

🔗📘 tinyurl.com/ydwentvd

✅The REPREVIO trial

Early vedolizumab after ileocolonic surgery drastically cuts severe #Crohns recurrence (23.3% vs. 62.2%) and boosts the chance of lower Rutgeerts scores (77.8%)! 💪

✨ Fewer flares, better outcomes‼️

15.12.2024 08:34 — 👍 1    🔁 0    💬 0    📌 0

💡 AI-assisted peer review is a promising tool, but adoption is fragmented & policies unclear.

🛟Safeguards against bias & breaches are critical.

💡With careful use, AI can enhance productivity while maintaining integrity.

‼️Continuous monitoring is essential! 🔍

04.12.2024 16:45 — 👍 0    🔁 0    💬 0    📌 0

📰 Key findings from top 100 medical journals:
🔹 78% provide AI peer review guidance.
❌ 59% prohibit AI use, mainly over confidentiality concerns (96%).
✅ 32% allow limited use with conditions like disclosure.
🌐 Global journals are more flexible than US/Europe-based ones.

04.12.2024 16:45 — 👍 0    🔁 0    💬 1    📌 0
Post image

🔥📚 Peer review is under pressure‼️

Can 🤖 AI be the solution?

📚🔗 tinyurl.com/44pt9m3f

A study dives into medical journals’ policies on AI-assisted peer review to uncover the trends. 🚀

04.12.2024 16:45 — 👍 1    🔁 0    💬 1    📌 0
Video thumbnail

🚀 First Virtual Reality in Endoscopy Training! 🎮🩺

A big 🙏 you to Boston Scientific, University Hospital Motol, 2nd Faculty of Medicine, Charles University, and 3NDO for their incredible support! 🙌👏

Pushing the boundaries of education and innovation in endoscopy! 🌍✨

01.12.2024 17:06 — 👍 3    🔁 0    💬 0    📌 0

💠Conclusion:

✅Resmetirom is a game-changer for MASH, but precise patient selection is 🔑. Let’s optimize outcomes! 💡

01.12.2024 06:09 — 👍 0    🔁 0    💬 0    📌 0
Post image Post image

💠Results:
📊 Target population: MASH with fibrosis stages 2-3.
✅ Promise: First FDA-approved 💊 offering hope for noncirrhotic MASH.

💠Challenges:
🩺 Noninvasive tools to identify F2-F3 patients.
⛔ Excluding advanced fibrosis until more data is available.

01.12.2024 06:09 — 👍 0    🔁 0    💬 1    📌 0
Post image

🚨 New Expert Panel Recomm. Alert 🚨

🔗📗 tinyurl.com/3he6rybk

💡Expert panel shares practical tips on initiating & monitoring #Resmetirom for #MASH with moderate to advanced fibrosis.

@cugastrohep.bsky.social @amergastroassn.bsky.social @aga-cgh.bsky.social

01.12.2024 06:09 — 👍 1    🔁 0    💬 1    📌 0
Post image

🧪 Combination therapy: TNF antagonists + immunomodulators > monotherapy.
🕒 Early escalation: Advanced therapies > step-up after 5-ASA failure.

30.11.2024 12:33 — 👍 1    🔁 0    💬 0    📌 0
Post image

✅ Top therapies: Infliximab, vedolizumab, upadacitinib, ozanimod, etrasimod, ustekinumab, risankizumab, and guselkumab.
👩‍⚕️ Advanced-naïve patients: Prefer higher-efficacy meds (e.g., infliximab) for remission.
🚫 Avoid thiopurine/methotrexate monotherapy for induction.

30.11.2024 12:33 — 👍 1    🔁 0    💬 1    📌 0
Post image

🚨 New AGA Guideline 🚨

🔗📗 tinyurl.com/mwc4ve42

💡An updated for the pharmacological management of moderate-to-severe #ulcerativecolitis.

A patient-centered, evidence-based guide to empower practitioners! 💊

@ibddoctor.bsky.social @ibd-afzali.bsky.social @bottomlineibd.bsky.social

30.11.2024 12:33 — 👍 1    🔁 0    💬 1    📌 0

@kraljan is following 16 prominent accounts